Inari Shares Skyrocket

Inari Shares Skyrocket As Stryker Will Acquire Medical Device Maker for $4.9B
Key Takeaways Shares of Inari Medical surged Monday afternoon and again Tuesday morning as reports of an imminent acquisition by Stryker turned into reality.Stryker will acquire Inari in an all-cash deal for $80 per share,
Stryker agrees to acquire Inari Medical for $4.9bn
Stryker has entered a definitive agreement to acquire complete issued and outstanding shares of Inari Medical’s common stock for $80 per share in cash, which equates to a total equity value of nearly $4.9bn. Inari is poised to enhance Stryker's footprint in the peripheral vascular sector, particularly in the venous thromboembolism (VTE) market.
Stryker Stock Falls Despite the Agreement to Acquire Inari Medical
Stryker Corporation SYK recently inked a definitive agreement to acquire all the issued and outstanding shares of common stock of Inari Medical, Inc. NARI for $80 per share in cash, representing a total fully diluted equity value of approximately $4.
Stryker confirms deal to purchase Inari Medical for $80 a share
Stryker announces agreement to acquire Inari Medical for $4.9 billion, resulting in a 21% jump in Inari's shares.
Stryker to Acquire Inari Medical in Deal Valued at $4.9 Billion
Inari makes mechanical thrombectomy solutions designed to treat peripheral vascular diseases. Stryker said the deal would be complementary to its neurovascular business.
Inari Medical soars on Stryker acquisition
Inari Medical Inc (NASDAQ:NARI) shares surged sharply after Stryker (NYSE:SYK) announced that it would acquire the medical device maker in an all-cash deal valued at $4.9 billion The acquisition strengthens Stryker’s position
Stryker to Buy Inari Medical in $4.9 Billion Deal
Stryker (SYK) agreed to acquire medical technology maker Inari Medical (NARI) in an all-cash deal worth roughly $4.9 billion as the company looks to boost its neurovascular and endovascular segments.
Inari Medical (NARI) was downgraded to a Hold Rating at BTIG
Inari Medical (NARI – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today. The company’s shares ...
Nasdaq1mon
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
including price controls, restrictions on coverage and reimbursements. Any unfavorable change in coverage for Inari Medical’s products will likely hurt their adoption, affecting top-line growth.
Wall Street Journal28d
Inari Medical Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing ...
Hold Rating Issued for Inari Medical Amidst Stryker Acquisition with Minimal Antitrust Concerns and Reasonable Valuation
Inari Medical (NARI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Sarcone ...
Inari Gets A Fair Bid As Stryker Buys Yet Another High-Growth Asset
Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal ...
Benzinga.com2mon
Inari Medical (NASDAQ:NARI) Stock, Insider Trading Activity
engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance. At Inari Medical ...
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More
Stock futures were rising modestly Tuesday, a day after tech shares helped lift the S&P 500 to its second straight gain.These ...
Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment
Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: ...